NOS2 and non-small cell lung carcinoma: A higher frequency of both subpopulations of M-MDSCs (CD14+CD15+HLA-DR−Lin− and CD14+CD15−HLA-DR−Lin−) expressed iNOS [0.3 ± 0.1%, (n = 6) and 0.4 ± 0.2%, (n = 6), resp., P < 0.02] in NSCLC patients compared to normal controls [0.002 ± 0.001%, (n = 6) and 0.02 ± 0.017%, (n = 6), resp.].